The partial tandem duplication of MLL (MLL-PTD) is found in 5-10% of patients with acute myeloid leukemia (AML) and normal cytogenetics. Its expression in leukemic blasts is coincident with a silenced wild-type (WT) MLL allele. We therefore generated mice expressing the Mll-PTD in the absence of Mll-WT. 
Introduction
Approximately 5-10% of patients with AML and normal cytogenetics present with rearrangement of the Mixed-Lineage Leukemia, (MLL, also known as ALL1 or HRX) gene as the result of a partial tandem duplication within a single MLL allele. 1, 2 In AML blasts harboring the somatic MLL PTD mutation, the MLL wild type (WT) allele is not expressed and when re-expressed, leukemic cell death was observed. 3 We previously reported on the Mll PTD/WT 'knock-in' mice that are fully viable with modest developmental defects, have aberrant gene expression and altered hematopoiesis, but do not develop leukemia. 4 RT-PCR on whole fetal liver, and c-kit+ and CD11b+ sorted populations was performed as previously described.
4,6
Chromatin Immunoprecipitation H3 (Lys4) dimethylation has been shown to occur as a direct result of MLL's SET domain methyltransferase activity. 4, 7 Therefore, ChIP assays were performed on 2 x 10 6 FLC using the EZ ChIP Assay Kit with the anti-dimethyl Histone H3 (Lys4) antibody (Millipore) according to the manufacturer's standard protocol. DNA was quantified using PCR and nested real time quantitative PCR with SYBR green incorporation (Applied Biosystems) using previously described methods.
Colony forming unit (CFU)-progenitor assays. Single cell suspensions were plated at a density of 50,000 cells/dish in M3434 methylcellulose (Stem Cell Technologies), and were performed according to the manufacturer's protocol (Stem Cell Technologies) and methods as previously described. Statistics. To evaluate whether significant differences in CFU-GEMM, CFU-GM, CFU-
BE existed between mouse genotypes as indicated in the Figure legend, paired t-tests
were carried out using siblings. Mll has now been shown to have very different functions in different subpopulations in the hematopoietic compartment. 8 Our results suggest that in some cases Mll function may have been lost and cannot be replaced by the Mll PTD allele, as in the case of Mll PTD/-early lethality at P1. However, in some cases such as HoxA gene overexpression and CFU-GM expansion, the Mll PTD appears to behave more as a dominant gain-offunction mutation since the quantifications performed for these experiments were similar between the Mll PTD/WT and Mll PTD/-genotypes, i.e., in the presence and absence of Mll WT, respectively. In contrast, differences in the number of BFU-E and CFU-GEMM progenitors seen between the Mll PTD/WT and Mll PTD/-genotypes reveal the lack of dominant activity by the Mll PTD allele. In this tissue-specific context, the Mll PTD may require interaction with the Mll WT in order to achieve the maximum manifestation of the abnormality. 
